Abstracts tagged "Behcet’s syndrome"

Abstract Number: 1339 • 2014 ACR/ARHP Annual Meeting
Is Psychological Status Related to Symptom Experience in Behçet’s Syndrome?
Robert Moots¹ and Sophie Campbell², ¹Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, ²Behcets Centre, Aintree University Hospital, Liverpool, United Kingdom
Background/Purpose Little is known about the impact of Behçet’s Syndrome (BS) within the UK. The recent establishment of National Centres of Excellence now allows a…
Abstract Number: 2758 • 2014 ACR/ARHP Annual Meeting
Predictive Factors for the Response to Infliximab Therapy in Patients with Behçet’s Disease
Salvatore D'Angelo¹, Pietro Leccese¹, Angela Padula¹, Angelo Nigro¹, Michele Gilio², Antonio Carriero¹, Carlo Palazzi¹ and Ignazio Olivieri¹, ¹Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy, ²San Carlo Hospital, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy
Background/Purpose: To identify the clinical factors predicting a good clinical response to Infliximab (IFX) therapy after 12 months in patients with Behçet’s disease (BD) refractory…
Abstract Number: 1212 • 2014 ACR/ARHP Annual Meeting
Behcets Disease in Females Due to Mutation in NEMO, the NF-Kb Essential Modulator
Alex Wessel¹, Spiros Vonortas², Jevgenia Zilberman-Rudenko³, Richard Siegel⁴ and Eric Hanson⁵, ¹5814 Beech Ave, NIH, Bethseda, MD, ²NIH, NIAMS, Bethesda, MD, ³Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴NIAMS, NIH, Bethesda, MD, ⁵National Institute of Health, Bethesda, MD
Background/Purpose: Behçet's disease (BD) is a chronic multi-system inflammatory disorder associated clinically with oral and genital ulceration, uveitis, erythema nodosum, and other inflammatory disease. The…
Abstract Number: 2760 • 2014 ACR/ARHP Annual Meeting
Interferon Alfa-Associated Depression in Patients with Behçet’s Syndrome
Yasin Keskin¹, Emire Seyahi², Cagri Poyraz³, Serdal Ugurlu¹, Yilmaz Ozyazgan⁴ and Hasan Yazici⁵, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Department of Psychiatry, Cerrahpasa Medical Faculty, University Of Istanbul, Istanbul, Istanbul, Turkey, ⁴Department of Ophthalmology, Cerrahpasa Medical Faculty University of Istanbul, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: Interferon (IFN) is an effective immune-modulatory agent in the medical management of eye disease of Behçet’s syndrome (BS). The agent is frequently associated with…
Abstract Number: 2762 • 2014 ACR/ARHP Annual Meeting
Atrophy of Hippocampal Region in Chronic Progressive Neuro-Behçet’s Disease
Hirotoshi Kikuchi¹, Kurumi Asako¹, Maki Takayama¹, Yoshitaka Kimura¹, Akiko Okamoto¹, Toshihiro Nanki^1,2, Hajime Kono¹ and Shunsei Hirohata³, ¹Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ²Department of Clinical Research Medicine, Teikyo University, Tokyo, Japan, ³Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Central nervous system involvement in Behçet's disease, usually called neuro-Behçet's disease (NB), can be classified into acute NB (ANB) and chronic progressive NB (CPNB)…
Abstract Number: 2763 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease
Shunsei Hirohata¹, Hirotoshi Kikuchi², Tetsuji Sawada³, Hiroko Nagafuchi⁴, Msataka Kuwana⁵, Mitsuhiro Takeno⁶ and Yoshiaki Ishigatsubo⁷, ¹Int Med/Rheumatol & Infec Dis, Kitasato Univ School of Med, Kanagawa, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Internal Medicine 3, Tokyo Medical University, Tokyo, Japan, ⁴Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ⁵Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan, ⁷Int Med & Clin Immunology, Yokohama City Grad Schl of Med, Yokohama, Japan
Background/Purpose: Chronic progressive neurological manifestations in Behcet's disease (BD) is characterized by progressive deterioration leading to disability either with or without a history of previous…
Abstract Number: 2744 • 2014 ACR/ARHP Annual Meeting
Mi-RNA Profile of Active Vascular BEHÇET’S Patients
Ahmet Mesut Onat¹, Ozan Gerenli², Bunyamin Kisacik¹, Mustafa Ulasli³, Gezmis Kimyon⁴, Yavuz Pehlivan⁵ and Serdar Oztuzcu⁶, ¹Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ²Rheumatology, Gaziantep UniversitySchool of Medicine, Gaziantep, Turkey, ³Genetics, Gaziantep UniversitySchool of Medicine, Gaziantep, Turkey, ⁴Department of Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁵Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, ⁶Genetcs, Gaziantep UniversitySchool of Medicine, Gaziantep, Turkey
Background/Purpose Behçet’s Disease (BD) is a systemic vasculitis that predominantly presented with oral aphtous ulcers and additionally at least two of the following findings like…
Abstract Number: 2745 • 2014 ACR/ARHP Annual Meeting
Plasma of Patients with Active Behçet´s Disease (BD) Increases Neutrophil Extracellular Trap Formation, Oxidative Metabolism and NADPH-Oxidase Expression in Normal and BD Neutrophils, and Carries Several Neutrophil Stimulating Factors
Sandro F. Perazzio^1,2, Paulo Vitor Soeiro Pereira³, Alexandre W. S. de Souza¹, Antonio Condino-Neto³ and Luis Eduardo C. Andrade^2,4, ¹Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ²Fleury Medicine and Health, Sao Paulo, Brazil, ³Immunology, ICB IV - Universidade de São Paulo, São Paulo, Brazil, ⁴Fleury Laboratories, Sao Paulo, Brazil
Background/Purpose Plasma factors seem to play a role in Behçet’s disease (BD) pathogenesis, especially by increasing phagocyte oxidative profile. No data exists regarding neutrophil extracellular…
Abstract Number: 2747 • 2014 ACR/ARHP Annual Meeting
Identification of Potential Serum Biomarkers for Behcet Disease By High Resolution Quantitative Proteomic Analysis
Yongjing CHENG Jr.¹, Xiaolin Sun², Yuling Chen Jr.³, Cibo Huang⁴, Haiteng Deng³ and Zhan-Guo Li⁵, ¹Rheumatology and Immunology Department, Beijing Hospital, Ministry of Health, Beijing, China, ²People's hospital,Peking University, Beijing, China, ³Tsing hua University, Beijing, China, ⁴Beijing hospital, Beijing, China, ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Behcet’s disease (BD) is a chronic, multisystemic vasculitis, pathogenesis of BD remains enigmatic. Diagnosis of BD is sometimes difficult, and until now, no specific…
Abstract Number: 2748 • 2014 ACR/ARHP Annual Meeting
Microparticles May Play a Role in Causing Thrombosis in Behçet’s Syndrome and Act As a Biomarker for Risk Management
Emon Khan¹, Nicola Ambrose¹, Michael A. Laffan² and Dorian O. Haskard³, ¹Department of Vascular Sciences, National Heart and Lung Institute, Imperial College, London, United Kingdom, ²Department of Haemostasis and Thrombosis, Imperial College, London, United Kingdom, ³Rheumatology, Imperial College, London, United Kingdom
Background/Purpose Thrombosis occurs in 20% of patients with Behçet’s Syndrome (BS) and leads to significant morbidity. There is no robust association between thrombosis in BS…
Abstract Number: 2749 • 2014 ACR/ARHP Annual Meeting
The Clinical Course of Acute Deep Vein Thrombosis of the Legs in Behçet’s Syndrome
Melike Melikoglu¹, Yesim Ozguler², Serdal Ugurlu³, Firat Cetinkaya⁴, Koray Tascilar², Emire Seyahi³, Vedat Hamuryudan³ and Hasan Yazici¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ²University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁴Radiology, Colormed Radiology Center, Istanbul, Turkey
Background/Purpose To determine the prospective clinical course of lower extremity deep vein thrombosis (LEDVT) in patients with Behçet’s syndrome (BS). Methods Consecutive BS patients with…
Abstract Number: 2750 • 2014 ACR/ARHP Annual Meeting
Effects of Anticoagulant Treatment on the Incidence of New Vascular Events in Patients with Behcet’s Disease with Vascular Involvement
Fatma Alibaz-Oner¹, Aslı Karadeniz², Sema Yilmaz³, Ayse Balkarli⁴, Gezmis Kimyon⁵, Ayten Yazici⁶, Muhammed Cinar⁷, Sedat Yilmaz⁷, Fatih Yildiz⁸, Sule Yasar Bilge⁹, Emre Bilgin¹⁰, Belkıs Nihan Şeniz¹¹, Ahmet Omma¹², Gozde Yildirim Cetin¹³, Yonca Cagatay¹⁴, Mehmet Sayarlioglu¹⁵, Yavuz Pehlivan¹⁶, Umut Kalyoncu¹⁷, Omer Karadag¹⁰, Timucin Kasifoglu⁹, Eren Erken⁸, Salih Pay⁷, Ayse Cefle⁶, Bunyamin Kisacik¹⁸, Ahmet Mesut Onat¹⁹, Veli Cobankara²⁰ and Haner Direskeneli¹, ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Internal Medicine, Marmara University, School of Medicine, Istanbul, Turkey, ³Department of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, ⁴Department of Rheumatology, Pamukkale University School of Medicine, Denizli, Turkey, ⁵Department of Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁶Department of Rheumatology, Kocaeli University, Kocaeli, Turkey, ⁷Rheumatology, Gulhane Military Medical Academy, Ankara, Turkey, ⁸Rheumatology, Cukurova University, School of Medicine, Adana, Turkey, ⁹Rheumatology, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey, ¹⁰Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹¹Rheumatology, Uludağ University, School of Medicine, Bursa, Turkey, ¹²Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ¹³Rheumatology, Kahramanmaras University School of Medicine, Kahramanmaras, Turkey, ¹⁴Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, ¹⁵Rheumatology, Ondokuz Mayis University School of Medicine, Samsun, Turkey, ¹⁶Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, ¹⁷PsAID taskforce, EULAR, Zurich, Switzerland, ¹⁸Rheumatology, Gaziantep University, School of Medicine, Gaziantep, Turkey, ¹⁹Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ²⁰Rheumatology, Pamukkale University, School of Medicine, Denizli, Turkey
Background/Purpose: Vascular involvement (VI) is one of the major causes of mortality and morbidity in Behcet's Disease (BD). There are no controlled studies for the…
Abstract Number: 2751 • 2014 ACR/ARHP Annual Meeting
18F-FDG PET/CT in Vascular Disease Due to Behçet’s Syndrome
Emire Seyahi¹, Metin Hallac², Betul Vatankulu³, Serdal Ugurlu¹, Melike Melikoglu⁴, Sebahattin Yurdakul¹ and Hasan Yazici⁴, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Department of Nuclear Medicine, Cerrahpasa Medical Faculty, University Of Istanbul, Istanbul, Turkey, ³Department of Nuclear Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT is considered as a useful tool in assessing active vascular inflammation in large vessel vasculitis. Lower extremity vein…
Abstract Number: 2752 • 2014 ACR/ARHP Annual Meeting
Budd-Chiari Syndrome Due to Behçet’s Syndrome: Some Patients Present without Liver Related Symptoms and Have a Better Outcome
Emire Seyahi¹, Erkan Caglar², Serdal Ugurlu¹, Fatih Kantarci³, Vedat Hamuryudan¹, Abdullah Sonsuz⁴, Melike Melikoglu⁵, Sebahattin Yurdakul¹ and Hasan Yazici⁵, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Gastroenterology, Department of Internal Medicine, Bakirkoy Research and Training Hospital, Istanbul, Turkey, ³Department of Radiology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey, ⁴Department of Gastroenterology, Cerrahpasa Medical Faculty of Istanbul Universit, Cerrahpasa Medical Faculty of Istanbul University, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose Behçet’s syndrome (BS) is a well recognized cause of Budd–Chiari syndrome (BCS), however, information about its clinical characteristics and outcome is limited. We had…
Abstract Number: 2624 • 2013 ACR/ARHP Annual Meeting
Evaluation of Asymptomatic Venous Disease By Venous Doppler Ultrasonography in Patients With Behcet’s Disease
Fatma Alibaz-Oner¹, Emrah Karatay², Ihsan Nuri Akpinar², Tülin Ergun³ and Haner Direskeneli¹, ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Radiology, Marmara University, School of Medicine, Istanbul, Turkey, ³Dermatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: One of the major causes of mortality and morbidity in Behcet’s disease (BD), especially in young males of Mediterranean origin, is vascular involvement. A…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].